Navigation Links
VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
Date:11/19/2010

BROOMFIELD, Colo., Nov. 19, 2010 /PRNewswire/ -- Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer (NSCLC) were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.  The intention of the biomarker analysis was to evaluate the ability of the blood-based test, VeriStrat, to predict patient outcomes with the erlotinib plus sorafenib combination regimen.

Forty-nine of 50 patients from the study had pretreatment serum samples available for analysis.  VeriStrat analysis classified 33 (67%) as likely to have "good" outcomes and 15 (31%) as likely to have "poor" outcomes.  Only one sample was classified as indeterminate.  VeriStrat Good patients had a significant improvement in overall survival compared with VeriStrat Poor patients (Hazard ratio= 0.30; CI: 0.12-0.74).  The median overall survival for VeriStrat Good patients was 13.7 months compared to 5.6 months for VeriStrat Poor patients. 

Researchers concluded that the proteomic test, VeriStrat, may identify a subset of patients that derive significant clinical benefit from first- line treatment of advanced NSCLC with dual targeted therapies.  Prospective studies are planned.

"This is the first study to demonstrate that a biomarker can identify patients who are likely to benefit from the erlotinib plus sorafenib combination," stated Egbert Smit, MD, PhD.  "This is exciting for lung cancer patients as the all-oral combination may be more tolerable than traditional platinum-based regimens, with similar efficacy.  More research is needed to fully define the role of this biomarker and identify the specific groups of patients that this combination may benefit."

About NSCLC:  As reported by the American Cancer Society, lung cancer is the leading cause of cancer death in the US.  NSCLC represents approximately 87% of lung cancer.  An estimated 215,000 new cases of lung cancer and 162,000 deaths due to lung cancer occurred in the US in 2008.  Treatment options include surgery, radiation therapy, chemotherapy and targeted biological therapies such as bevacizumab (Avastin®) and erlotinib (Tarceva®).  Less than 5% of advanced NSCLC patients survive for 5 years, emphasizing the need for improved patient selection to maximize drug efficacy.  

About VeriStrat:  VeriStrat is a proteomic serum test for patients with advanced NSCLC.  The test identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs).  Samples are processed in Biodesix' CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment.  VeriStrat has been validated in clinical studies with over 1500 patients.  Biodesix is engaging in additional studies to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other EGFRIs.  For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.

About Biodesix:  Biodesix is a fully integrated molecular diagnostic company developing products that support excellence in clinical decision making and improve patient care.  The Company's goal is to give physicians more information to understand the patient and their disease.  Understanding the clinically meaningful information contained within each patient's molecular profile leads to better care and better outcomes.  The Company's unique approach is based on ProTS®, proprietary technology which exploits the power of mass spectrometry and enables the discovery of specific molecular profiles that can be used to better characterize the patient and their disease. Biodesix collaborates with investigators to address key clinical questions, and partners with biotechnology and pharmaceutical companies for development of companion diagnostics and improved targeting of therapies in clinical trials.  For more information about Biodesix, please visit the Company's website at www.Biodesix.com

This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Biodesix
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory
2. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
3. Research Identifies Need for Improved Understanding of Sickle Cell Disease in Adulthood
4. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
5. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
6. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
7. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
8. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Nemours Center for Childhood Cancer Research Team at the Alfred I. duPont Hospital for Children Identifies the Function of a Biomarker Present in Prostate Cancer Cells: New Insight into Therapeutic Benefit for Patients with Advanced Prostate Cancer
11. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):